Comparative Pharmacology
Head-to-head clinical analysis: ARGATROBAN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARGATROBAN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
ARGATROBAN IN 0.9% SODIUM CHLORIDE vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, and XIII, and platelet aggregation.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Continuous IV infusion: 2 mcg/kg/min, adjusted to maintain aPTT 1.5-3 times baseline. Maximum initial infusion rate is 10 mcg/kg/min.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life is 39–51 minutes in healthy subjects; prolonged to 181–269 minutes in patients with hepatic impairment. Clinical context: Short half-life allows rapid reversal of anticoagulation upon discontinuation.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Primarily hepatic (biliary) excretion: approximately 65% eliminated via bile into feces; renal excretion accounts for about 22% as unchanged drug and metabolites.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte